Systems biology meets -omic technologies: Novel approaches to biomarker discovery and companion diagnostic development

Expert Review of Molecular Diagnostics

Volumn 15, Issue 2, 2015, Pages 255-265

  Caberlotto, Laura ^a   Lauria, Mario ^a  

^a UNIVERSITY OF TRENTO   (Italy)

Author keywords

companion diagnostic; molecular biomarkers; network analysis; systems biology; systems medicine; systems pharmacology

Indexed keywords

BIOLOGICAL MARKER;

BIOMICS; EPIGENETICS; GENOMICS; HUMAN; LIPIDOMICS; METABOLOMICS; MOLECULAR BIOLOGY; MOLECULAR DIAGNOSIS; PROTEOMICS; REVIEW; SYSTEMS BIOLOGY; TRANSCRIPTOMICS; METABOLISM; PERSONALIZED MEDICINE;

BIOLOGICAL MARKERS; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; SYSTEMS BIOLOGY;

EID: 84921370127     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2015.975214     Document Type: Review

References (67)

1. Strimbu K, Tavel JA. What are biomarkers?. Curr Opin HIV AIDS 2010;5(6):463-6
2. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69(3):89-95
3. Drucker E, Krapfenbauer K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. EPMA J 2013;4(1):7
4. Issaq HJ, Waybright TJ, Veenstra TD. Cancer biomarker discovery: opportunities and pitfalls in analytical methods. Electrophoresis 2011;32(9):967-75
5. FDA. Nucleic acid based tests, 2014. Available from: www.fda.gov/medical devices/productsandmedicalprocedures/.invitrodiagnostics/ucm330711.htm [Accessed 19 September 2014]
6. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353(9154): 717-19
7. Kimura T, Okamoto K, Miyamoto H, et al. Clinical benefit of high-sensitivity KRAS mutation testing in metastatic colorectal cancer treated with anti-EGFR antibody therapy. Oncology 2012;82(5):298-304
8. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev 2009;23(7):781-3
9. Bird A. Perceptions of epigenetics. Nature 2007;447(7143):396-8
10. Bock C. Epigenetic biomarker development. Epigenomics 2009;1(1):99-110
11. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358(11):1148-59
12. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 2008;9(6): 465-76
13. Laird PW. Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet 2010;11(3):191-203
14. Kondo Y, Shen L, Cheng AS, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008;40(6): 741-50
15. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435(7043): 834-8
16. Xu M-D, Qi P, Du X. Long non-coding RNAs in colorectal cancer: implications for pathogenesis and clinical application. Mod Pathol 2014;27(10):1310-20
17. Guest PC, Gottschalk MG, Bahn S. Proteomics: improving biomarker translation to modern medicine?. Genome Med 2013;5(2):17
18. Chandramouli K, Qian P-Y. Proteomics: challenges, techniques and possibilities to overcome biological sample complexity. Hum Genomics Proteomics 2009;1: no. 239204
19. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 2008;48:653-83
20. Ji Y, Hebbring S, Zhu H, et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther 2011;89(1):97-104
21. Lam SM, Shui G. Lipidomics as a principal tool for advancing biomedical research. J Genet Genomics 2013;40(8):375-90
22. Xuewu Z. Omics technologies in cancer biomarker discovery. L Bioscience 2011
23. Jacobs RJ, Voorneveld PW, Kodach LL, Hardwick JCH. Cholesterol metabolism and colorectal cancers. Curr Opin Pharmacol 2012;12(6):690-5
24. Zaidi N, Lupien L, Kuemmerle NB, et al. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res 2013;52(4):585-9
25. McEvoy J, Baillie RA, Zhu H, et al. Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics. PLoS One 2013; 8(7):e68717
26. Sewall CH, Bell DA, Clark GC, et al. Induced gene transcription: implications for biomarkers. Clin Chem 1995;41(12 Pt 2): 1829-34
27. Riedmaier I, Pfaffl MW, Meyer HHD. The physiological way: monitoring RNA expression changes as new approach to combat illegal growth promoter application. Drug Test Anal 4 Suppl 2012;1:70-4
28. Gordon GJ, Jensen R V, Hsiao L-L, et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 2002;62(17): 4963-7
29. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747-52
30. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406(6795):536-40
31. Nguyen B, Cusumano PG, Deck K, et al. Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients. Ann Surg Oncol 2012;19(10): 3257-63
32. Kaklamani V. A Genetic Signature Can Predict Prognosis and Response to Therapy in Breast Cancer: Oncotype DX. Expert Rev Mol Diagn 2006;6(6):803-9
33. Mook S, Van't Veer LJ, Rutgers EJT, et al. Individualization of therapy using Mammaprint: from development to the MINDACT Trial. Cancer Genomics Proteomics 2007;4(3):147-55
34. Yamani MH, Taylor DO, Rodriguez ER, et al. Transplant vasculopathy is associated with increased AlloMap gene expression score. J Heart Lung Transplant 2007;26(4): 403-6
35. Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes?. Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 2012; 12(6):621-8
36. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2006;2(12):689-700
37. Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol 2012;6(2):155-76
38. In Vitro companion diagnostic devices, 2014. Available from: fda.gov/downloads/.MedicalDevices/DeviceRegulationand Guidance/uidanceDocuments/UCM262327. pdf [Accessed 19 September 2014]
39. Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-Throughput sequencing: a pilot study. Sci Transl Med 2011;3(111): 111ra121
40. MERCK, 2013. Available from: www. merck.com/index.html [Accessed 19 September 2014]
41. Halim SA, Newby LK, Ohman EM. Biomarkers in cardiovascular clinical trials: past, present, future. Clin Chem 2012; 58(1):45-53
42. Ortea I, Roschitzki B, Ovalles JG, et al. Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis. J Proteomics 2012;77:372-82
43. Valenti WM. Companion diagnostic tests in HIV medicine: the road to personalized medicine. AIDS Read 2007;17(11):546-9
44. Bruggeman FJ, Hornberg JJ, Boogerd FC, Westerhoff H V. Introduction to systems biology. EXS 2007;97:1-19
45. Chuang HY, Hofree M, Ideker T. A decade of systems biology. Annu Rev Cell Dev Biol 2010;26:721-44
46. Yu D, Kim M, Xiao G, Hwang TH. Review of biological network data and its applications. Genomics Inform 2013;11(4): 200-10
47. Auffray C, Chen Z, Hood L. Systems medicine: the future of medical genomics and healthcare. Genome Med 2009;1(1):2
48. Chen Y, Zhu J, Lum PY, et al. Variations in DNA elucidate molecular networks that cause disease. Nature 2008;452(7186): 429-35
49. Emilsson V, Thorleifsson G, Zhang B, et al. Genetics of gene expression and its effect on disease. Nature 2008;452(7186):423-8
50. Fan Y, Resnick SM, Wu X, Davatzikos C. Structural and functional biomarkers of prodromal Alzheimer's disease: a high-dimensional pattern classification study. Neuroimage 2008;41(2):277-85
51. Antila K, Lötjönen J, Thurfjell L, et al. The PredictAD project: development of novel biomarkers and analysis software for early diagnosis of the Alzheimer's disease. Interface Focus. 2013;3(2):20120072
52. Xie L, Xie L, Kinnings SL, Bourne PE. Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu Rev Pharmacol Toxicol 2012;52:361-79
53. Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics 2009; 25(19):2466-72
54. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003;348(6):538-49
55. Mougey EB, Feng H, Castro M, et al. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 2009;19(2): 129-38
56. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304(16):1812-20
57. Lamb J. The connectivity map: a new tool for biomedical research. Nat Rev Cancer 2007;7(1):54-60
58. Iorio F, Bosotti R, Scacheri E, et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci USA 2010;107(33): 14621-6
59. Winter GE, Rix U, Carlson SM, et al. Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nat Chem Biol 2012;8(11):905-12
60. Xie L, Ge X, Tan H, et al. Towards structural systems pharmacology to study complex diseases and personalized medicine. PLoS Comput Biol 2014;10(5):e1003554
61. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005;365(9458):488-92
62. Ein-Dor L, Zuk O, Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci USA 2006;103(15): 5923-8
63. Lauria M. Rank-based transcriptional signatures: a novel approach to diagnostic biomarker definition and analysis. Syst Biomed 2013;1(4):35-46
64. Tarca AL, Lauria M, Unger M, et al. Strengths and limitations of microarray-based phenotype prediction: lessons learned from the IMPROVER Diagnostic Signature Challenge. Bioinformatics 2013;29(22):28
65. Lauria M
66. Carreira S, Romanel A, Goodall J, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med 2014;6(254): 254ra125
67. Stanberry L, Mias G, Haynes W, et al. Integrative analysis of longitudinal metabolomics data from a personal multi-omics profile. Metabolites 2013;3(3): 741-60